12:00 AM
 | 
Jan 05, 2015
 |  BC Week In Review  |  Company News  |  Deals

MacroGenics, J&J deal

MacroGenics will grant Johnson & Johnson’s Janssen Biotech Inc. unit exclusive, worldwide rights to preclinical candidate MGD011. The compound is a bispecific antibody against CD19 and CD3 developed using Dual-Affinity Re-Targeting (DART) technology. Janssen...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >